Literature DB >> 21826372

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Sebastian Newrzela1, Kerstin Cornils, Tim Heinrich, Julia Schläger, Ji-Hee Yi, Olga Lysenko, Janine Kimpel, Boris Fehse, Dorothee von Laer.   

Abstract

Several cases of T-cell leukemia caused by gammaretroviral insertional mutagenesis in children treated for x-linked severe combined immunodeficiency (SCID) by transplantation of autologous gene-modified stem cells were reported. In a comparative analysis, we recently showed that mature T cells, on the contrary, are highly resistant to transformation by gammaretroviral gene transfer. In the present study, we observed immortalization of a single T-cell clone in vitro after gammaretroviral transduction of the T-cell protooncogene LMO2. This clone was CD4/CD8 double-negative, but expressed a single rearranged T-cell receptor. The clone was able to overgrow nonmanipulated competitor T-cell populations in vitro, but no tumor formation was observed after transplantation into Rag-1 deficient recipients. The retroviral integration site (RIS) was found to be near the IL2RA and IL15RA genes. As a consequence, both receptors were constitutively upregulated on the RNA and protein level and the immortalized cell clone was highly IL-2 dependent. Ectopic expression of both, the IL2RA chain and LMO2, induced long-term growth in cultured primary T cells. This study demonstrates that insertional mutagenesis can contribute to immortalization of mature T cells, although this is a rare event. Furthermore, the results show that signaling of the IL-2 receptor and the protooncogene LMO2 can act synergistically in maligniant transformation of mature T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826372      PMCID: PMC3321800          DOI: 10.2119/molmed.2010.00193

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

Review 1.  Fatal leukemia in interleukin-15 transgenic mice.

Authors:  T A Fehniger; K Suzuki; J B VanDeusen; M A Cooper; A G Freud; M A Caligiuri
Journal:  Blood Cells Mol Dis       Date:  2001 Jan-Feb       Impact factor: 3.039

2.  Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro.

Authors:  Thomas M Schmitt; Renée F de Pooter; Matthew A Gronski; Sarah K Cho; Pamela S Ohashi; Juan Carlos Zúñiga-Pflücker
Journal:  Nat Immunol       Date:  2004-03-21       Impact factor: 25.606

3.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

Authors:  Alessandra Recchia; Chiara Bonini; Zulma Magnani; Fabrizia Urbinati; Daniela Sartori; Sara Muraro; Enrico Tagliafico; Attilio Bondanza; Maria Teresa Lupo Stanghellini; Massimo Bernardi; Alessandra Pescarollo; Fabio Ciceri; Claudio Bordignon; Fulvio Mavilio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.

Authors:  Olga S Kustikova; Bernhard Schiedlmeier; Martijn H Brugman; Maike Stahlhut; Stefan Bartels; Zhixiong Li; Christopher Baum
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

5.  Peaceful coexistence or clonal dominance?

Authors:  Dorothee von Laer
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

6.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Authors:  R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

7.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors:  Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

8.  Resistance of mature T cells to oncogene transformation.

Authors:  Sebastian Newrzela; Kerstin Cornils; Zhixiong Li; Christopher Baum; Martijn H Brugman; Marianne Hartmann; Johann Meyer; Sylvia Hartmann; Martin-Leo Hansmann; Boris Fehse; Dorothee von Laer
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

9.  Regulation of CD27 expression on subsets of mature T-lymphocytes.

Authors:  R Q Hintzen; R de Jong; S M Lens; M Brouwer; P Baars; R A van Lier
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

10.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

View more
  11 in total

1.  Genome editing technologies: defining a path to clinic.

Authors:  Jacqueline Corrigan-Curay; Marina O'Reilly; Donald B Kohn; Paula M Cannon; Gang Bao; Frederic D Bushman; Dana Carroll; Toni Cathomen; J Keith Joung; David Roth; Michel Sadelain; Andrew M Scharenberg; Christof von Kalle; Feng Zhang; Robert Jambou; Eugene Rosenthal; Morad Hassani; Aparna Singh; Matthew H Porteus
Journal:  Mol Ther       Date:  2015-05       Impact factor: 11.454

2.  Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Authors:  Matthew J Frigault; Jihyun Lee; Maria Ciocca Basil; Carmine Carpenito; Shinichiro Motohashi; John Scholler; Omkar U Kawalekar; Sonia Guedan; Shannon E McGettigan; Avery D Posey; Sonny Ang; Laurence J N Cooper; Jesse M Platt; F Brad Johnson; Chrystal M Paulos; Yangbing Zhao; Michael Kalos; Michael C Milone; Carl H June
Journal:  Cancer Immunol Res       Date:  2015-01-19       Impact factor: 11.151

3.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Authors:  Belinda Berdien; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Nicolaus Kröger; Djordje Atanackovic; Boris Fehse
Journal:  Hum Vaccin Immunother       Date:  2013-02-21       Impact factor: 3.452

Review 4.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

5.  Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

Authors:  Tim Heinrich; Benjamin Rengstl; Alexander Muik; Mina Petkova; Frederike Schmid; Robin Wistinghausen; Kathrin Warner; Giuliano Crispatzu; Martin-Leo Hansmann; Marco Herling; Dorothee von Laer; Sebastian Newrzela
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

6.  OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.

Authors:  Andreas A Hombach; Johannes Heiders; Marcel Foppe; Markus Chmielewski; Hinrich Abken
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

7.  Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.

Authors:  Kenneth P Micklethwaite; Kavitha Gowrishankar; Brian S Gloss; Ziduo Li; Janine A Street; Leili Moezzi; Melanie A Mach; Gaurav Sutrave; Leighton E Clancy; David C Bishop; Raymond H Y Louie; Curtis Cai; Jonathan Foox; Matthew MacKay; Fritz J Sedlazeck; Piers Blombery; Christopher E Mason; Fabio Luciani; David J Gottlieb; Emily Blyth
Journal:  Blood       Date:  2021-10-21       Impact factor: 25.476

Review 8.  The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.

Authors:  Tessa Gargett; Michael P Brown
Journal:  Front Pharmacol       Date:  2014-10-28       Impact factor: 5.810

9.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09

Review 10.  Genetically engineered T cells for the treatment of cancer.

Authors:  M Essand; A S I Loskog
Journal:  J Intern Med       Date:  2013-02       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.